By contrast, MSH6’s low expression level was significantly linked with poor FP (P=0.019), OS (P=6e-04) and PPS (P=1.7e-05) prognosis in patients with gastric cancer (Supplementary Figure 2C). Here, MSH6 is linked to gastric cancer.